CRDF — Cardiff Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1213037 ·
Last close
$0.85
Market Cap
$65.85M
52W High
$3.31
52W Low
$0.71
ADV30
1,291,952
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 171,000 | — | -9,219,000 | -8,857,000 | 36,414,000 | 12,060,000 | 8,316,000 |
| Jun 2026 | 104,000 | — | -9,615,000 | -9,232,000 | 37,329,000 | 9,197,000 | 10,797,000 |
| Mar 2026 | 41,000 | — | -12,850,000 | -12,345,000 | 49,172,000 | 8,544,000 | 14,463,000 |
| Dec 2025 | 243,000 | — | -7,827,000 | -7,216,000 | 61,884,000 | 17,470,000 | 16,496,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,854,000
Investing CF
$36,435,000
Financing CF
$2,832,000
CapEx
$-18,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.70
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-451,607,000
Inventory
—
Receivables
$189,000
ST Investments
$25,323,000
EBIT TTM
$-42,266,000
Pretax Income TTM
$-40,051,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$508,000
EBITDA
$-41,915,000
Free Cash Flow
$-24,304,250
Enterprise Value
$22,540,824
Total Cash
$34,520,000
Total Debt
$457,000
Shares Out
77,795,249
Trailing EPS
$-0.54
Book Value
$0.66
ROE
-94.1%
ROA
-46.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 593,000 | -48,960,000 | -45,851,000 | 61,884,000 | 16,496,000 | 45,388,000 | -37,923,000 |
| Dec 2024 | 683,000 | -48,651,000 | -45,431,000 | 97,190,000 | 14,241,000 | 82,949,000 | -37,693,000 |
| Dec 2023 | 488,000 | -45,412,000 | -41,441,000 | 81,637,000 | 11,898,000 | 69,739,000 | -30,887,000 |
| Dec 2022 | 386,000 | -39,902,000 | -38,704,000 | 116,191,000 | 9,848,000 | 106,343,000 | -33,820,000 |
TTM Snapshot
Revenues TTM
$508,000
NetIncome TTM
$-40,051,000
OpCashFlow TTM
—
Assets (Latest)
$37,329,000
Forward EPS
$-0.52
Max Pain — expiry 2027-01-15
max pain strike: $1.00 · spot: $0.84 · call oi: 6,430 · put oi: 63
Expected Move to 2027-01-15:
±$0.62
(74.40%) —
implied range
$0.21 –
$1.46
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $66.22M | $6.50 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $63.91M | $4.59 | — |
| VISK | Viskase Holdings, Inc. | $63.49M | $4.43 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $68.60M | $0.74 | — |
| NMRA | Neumora Therapeutics, Inc. | $62.85M | $0.33 | — |
News headlines (Yahoo Finance, 1h cache)
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
2026-11-16 12:00 · Yahoo
Cardiff Oncology: Q3 Earnings Snapshot
2026-11-12 12:21 · Yahoo
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
2026-11-12 12:00 · Yahoo
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
2026-11-03 12:00 · Yahoo
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
2026-10-27 20:05 · Yahoo
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
2026-10-21 20:05 · Yahoo
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
2026-09-14 12:30 · Yahoo
Cardiff Oncology to Participate in September 2026 Conferences
2026-09-02 11:00 · Yahoo
CRDF: Second Quarter Earnings
2026-08-17 09:47 · Yahoo
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
2026-08-11 20:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.